Drug profile · INN
dorzolamide hydrochloride
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE
dorzolamide hydrochloride (DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE) is a carbonic anhydrase ii inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — dorzolamide hydrochloride
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
dorzolamide hydrochloride (DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE) is a carbonic anhydrase ii inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Carbonic anhydrase II inhibitor
Primary target: Carbonic anhydrase 2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dorzolamide hydrochloride?
dorzolamide hydrochloride (DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE) is a carbonic anhydrase ii inhibitor. Associated with Regeneron Ireland Designated Activity Company (DAC). Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for dorzolamide hydrochloride?
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE is a marketed brand name for dorzolamide hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dorzolamide hydrochloride?
dorzolamide hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.